Emory-developed COVID-19 vaccine safe, effective in animal models
Woodruff Health Sciences Center | Feb. 4, 2021
Researchers at Yerkes National Primate Research Center and Emory Vaccine Center have developed a COVID-19 vaccine that has proven safe and effective in mice and monkeys. The results were published online Thursday, Feb. 4 in Immunity.
The Emory COVID-19 vaccine induces protective immunity via the platform of modified vaccinia Ankara (MVA), a harmless version of a poxvirus that is well-known for its use in HIV/AIDS vaccines. Like the Moderna and Pfizer vaccines, the MVA COVID-19 vaccine induces strong neutralizing antibodies, which support the immune system’s ability to fight infections. The MVA COVID-19 vaccine also induces killer CD8 T cells, providing a multi-pronged approach to halting SARS-CoV-2.
In addition, Emory researchers say the vaccine is easily adaptable to address disease variants and can be used in combination with existing vaccines to improve their ability to combat variants and has the potential to be equally effective with a single dose.
Lead researcher Rama Amara, PhD, built the MVA COVID-19 vaccine based on his more than 20 years of experience working with MVA and animal models to develop an HIV/AIDS vaccine. He and his Yerkes-based research team tested two MVA SARS-CoV-2 vaccines in mice. One of them, MVA/S, used the complete spike protein of coronavirus to induce strong neutralizing antibodies and a strong killer CD8 T cell response against SARS-CoV-2.
“Generating neutralizing antibodies is an important component of a successful COVID-19 vaccine because the antibodies can block the virus from entering the body’s cells,” says Amara, who is Charles Howard Candler professor of microbiology and immunology at Emory University School of Medicine and a researcher in Yerkes’ Division of Microbiology and Immunology. “It’s as important to activate CD8 T cells that can clear infected cells, so this allows us to approach halting the virus two ways simultaneously. The CD8 T cells also provide ongoing value because they are key to working against other variants of the virus, especially if antibodies fail.”
Based on the encouraging study results in mice, Amara's team advanced the MVA/S COVID-19 vaccine into a study with 10 rhesus monkeys at Yerkes. For five animals, the researchers gave two doses of the vaccine a month apart and then challenged them with SARS-CoV-2. The researchers also challenged a group of five monkeys that received a placebo MVA vaccine, which did not contain any genes from the COVID-19 virus. The virus grew to high levels in the lungs of all five placebo animals by the second day, but was below detection limits in all five MVA/S-vaccinated animals.
“Comparing the virus in vaccine and placebo groups provided clear results the MVA/S vaccine is safe and effective against SARS-CoV-2,” says Amara. “These results are even more promising because the MVA/S-vaccinated animals did not show any signs of inflammation in the lungs such as what medical professional are seeing in humans who have COVID-19.”
Rafi Ahmed, PhD, director of the Emory Vaccine Center, credits Amara for his comprehensive approach:
“Based on decades of research, we know MVA vaccines are safe, effective and can be used in combination with other vaccines, including mRNA vaccines, to enhance the immune system’s response. The Emory MVA COVID-19 vaccine, which builds on the MVA HIV vaccine Dr. Amara co-developed that recently completed phase 2a human clinical trials, scores multiple goals by producing neutralizing antibodies, inducing killer CD8 T cells and preventing lung inflammation. This multi-layered approach to developing a COVID-19 vaccine is well positioned to fight the current strain of SARS-CoV-2 as well as the variants we’re beginning to see.”
“My research team and I as well as the entire Yerkes community are excited to move the Emory MVA COVID-19 vaccine forward,” says Amara. “The world needs multiple COVID-19 vaccines to meet the demand. Our vaccine can stand alone as well as complement the available mRNA versions. It’s a perfect combination of scientific expertise and collaboration, and commitment to improving human health.”
Amar's team will continue their work on COVID-19 vaccines, with one study focusing on the effectiveness of a single dose of the Emory MVA COVID-19 vaccine. A convenient single dose regimen could prove especially valuable to ensure a high rate of vaccine uptake. Amara received two FastGrant awards to supplement his NIAID grant and expedite this follow-up COVID-19 research.
In a second study, Amara’s team is focusing on inducing broader T cell responses capable of fighting new COVID-19 variants and other human coronaviruses.
“The newly designed vaccines aim to induce T cells against multiple other genes of the virus in addition to targeting the spike protein,” says Amara. “This requires inserting multiple genes of the coronavirus into the vaccine, which can be challenging. MVA, however, is well-suited for this because of its unique capacity to carry extra genes.”
Amara’s research team includes Nandakishore Routhu, PhD (postdoc), Sailaja Gangadhara, PhD (research associate), Narayanaiah Cheedarla, PhD (postdoc), and Venkata Satish Bollimpelli, PhD (postdoc), all four co-lead authors, as well as Ayalensh Shiferaw (research specialist). Amara and his team worked in close collaboration with the laboratories of Mehul Suthar, PhD, and Steve Bosinger, PhD. Suthar is an assistant professor in the Emory SOM Department of Pediatrics and an EVC researcher. Bosinger is an assistant professor in the SOM Department of Pathology & Laboratory Medicine, an EVC researcher as well as a researcher in Yerkes’ Division of Microbiology and Immunology, and director, Yerkes Nonhuman Primate (NHP) Genomics Core.
In addition to the NIAID grant 3R01AI148378-01S1, the MVA vaccine study reported in this release is supported in part by the Yerkes National Primate Research Center base grant P51OD011132 from the NIH Office of the Director, Office of Research Infrastructure Programs.
Grant amounts (direct + indirect):
3R01AI148378-01S1 $582,625/for 2 years
Fast grant 1, $250,000
Fast grant 2, $350,000
Note: The amounts listed above are for the full grants. Only a portion of the P51 will support infrastructure needs of the COVID-19 vaccine study reported in this news release.